Table 4.

Association between APOL1 high-risk variant status and eGFR in Penn Medicine Biobank using multivariable rank-based regression and eGFR slope using multivariable linear regression.

		Model 1*		Model 2**
		Effect Estimate (SE)	p value	Effect Estimate (SE)	p value
eGFR
Overall	n=1837	−16.00 (2.21)	6.28 × 10−13	−15.36 (2.32)	4.30 × 10−11
CKD/ESRD†	n=618	−11.95 (2.22)	1.05 × 10−7	−13.16 (2.24)	7.74 × 10−9
eGFR slope
Overall	n=1362	3.46 × 10−4 (5.70 × 10−4)	0.54	4.57 × 10−4 (5.74 × 10−4)	0.43
CKD††	n=354	2.94 × 10−4 (1.04 × 10−3)	0.78	1.88 × 10−4 (1.04 × 10−3)	0.86

^*Model 1 is adjusted for age, age-squared, gender, and principal components 1–10 of genetic ancestry

Model 1 is adjusted for age, age-squared, gender, and principal components 1–10 of genetic ancestry

^**Model 2 additionally adjusts for mean body mass index, mean blood glucose, mean systolic blood pressure, and smoking status (current/former versus never)

Model 2 additionally adjusts for mean body mass index, mean blood glucose, mean systolic blood pressure, and smoking status (current/former versus never)

^†CKD/ESRD defined as eGFR<60 mL/min/1.73 m² or presence of at least two diagnosis codes for dialysis or renal transplant

CKD/ESRD defined as eGFR<60 mL/min/1.73 m² or presence of at least two diagnosis codes for dialysis or renal transplant

^††CKD defined as eGFR≥15 mL/min/1.73 m² and <60 mL/min/1.73 m²

CKD defined as eGFR≥15 mL/min/1.73 m² and <60 mL/min/1.73 m²

Abbreviations: ß = unstandardized coefficient, CI = confidence interval, eGFR = estimated glomerular filtration rate, SE = standard error